Gene therapy’s one-and-done mindset proved “a boon and a bane,” said Avak Kahvejian, general partner at Flagship Pioneering. “You have one shot to get it right, is what that really means,” and his firm founded Ring Therapeutics Inc. to design redosable drugs in the space.
Biopharmas raising money in public or private financings, including: Angelini, Aristea, Azurrx, Caribou, Cybin, DA32, Deep Genomics, Idorsia, Intelgenx, Mink.
Hongyun Biotech Co. Ltd. raised ¥100 million (US$15.5 million) in a series B round to move its new generation EGFR inhibitor, RC-01, to the IND stage in China and the U.S. for non-small-cell lung carcinoma (NSCLC). The plan is to finish the IND filing by the end of this year and start the trial in 2022.
LONDON – Artios Ltd. has closed a $153 million series C, positioning it to intensify clinical development of its two lead programs, whilst applying its DNA damage response platform to exploit the full spectrum of vulnerabilities presented by inhibition of DNA damage repair enzymes.
NHS England has announced a new £340 million (US$481 million) Innovative Medicines Fund, as the country grapples with the issue of bringing ultra-pricey specialist medicines to patients on the country’s taxpayer-funded health care system.
DUBLIN – Anocca AB raised $47 million in a series B round to advance its T-cell-based immunotherapies expressing recombinant T-cell receptors (TCRs) toward clinical trials in cancer and to build out its manufacturing capacity at its base in Södertälje, Sweden.
RSS
